- Home
- SCNX vs ALGS Comparison
SCNX vs ALGS Comparison
Compare SCNX & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- ALGS
- Stock Information
- Founded
- SCNX 2010
- ALGS 2018
- Country
- SCNX United States
- ALGS United States
- Employees
- SCNX N/A
- ALGS N/A
- Industry
- SCNX Other Pharmaceuticals
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- ALGS Health Care
- Exchange
- SCNX Nasdaq
- ALGS Nasdaq
- Market Cap
- SCNX 33.6M
- ALGS 36.0M
- IPO Year
- SCNX 2020
- ALGS 2020
- Fundamental
- Price
- SCNX $0.90
- ALGS $5.30
- Analyst Decision
- SCNX
- ALGS Strong Buy
- Analyst Count
- SCNX 0
- ALGS 1
- Target Price
- SCNX N/A
- ALGS $70.00
- AVG Volume (30 Days)
- SCNX 76.0K
- ALGS 163.7K
- Earning Date
- SCNX 05-12-2025
- ALGS 05-06-2025
- Dividend Yield
- SCNX N/A
- ALGS N/A
- EPS Growth
- SCNX N/A
- ALGS N/A
- EPS
- SCNX N/A
- ALGS N/A
- Revenue
- SCNX $146,901.00
- ALGS $3,270,000.00
- Revenue This Year
- SCNX N/A
- ALGS N/A
- Revenue Next Year
- SCNX N/A
- ALGS N/A
- P/E Ratio
- SCNX N/A
- ALGS N/A
- Revenue Growth
- SCNX N/A
- ALGS N/A
- 52 Week Low
- SCNX $0.69
- ALGS $3.76
- 52 Week High
- SCNX $23.77
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- ALGS 43.34
- Support Level
- SCNX N/A
- ALGS $5.12
- Resistance Level
- SCNX N/A
- ALGS $6.12
- Average True Range (ATR)
- SCNX 0.00
- ALGS 0.54
- MACD
- SCNX 0.00
- ALGS 0.09
- Stochastic Oscillator
- SCNX 0.00
- ALGS 13.53
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.